Armata Pharmaceuticals Inc (ARMP)
:ARMP
Top Page
Armata Pharmaceuticals
(ARMP)
Select Model
Select Model
Rating:55Neutral
Price Target:
$12.00
▼(-6.83% Downside)
Action:ReiteratedDate:04/08/26
The score is held down primarily by very weak financial performance (persistent losses, ongoing cash burn, and negative equity), partially offset by strong bullish technical momentum and favorable clinical/regulatory milestones (FDA Phase 3 support and QIDP designation). Valuation remains unattractive/unclear due to negative earnings and no dividend yield.
Positive Factors
FDA End-of-Phase 2 Support
FDA written End-of-Phase 2 support materially de-risks the regulatory path by confirming Phase 2 data can justify a pivotal trial. This validation supports a clear development plan toward a registrational Phase 3, increases credibility with partners and funders, and solidifies a multi-quarter development roadmap.
Negative Factors
Persistent Losses & Negative Equity
Sustained multiyear losses and negative equity signal a strained capital base and reduce financial flexibility. Over the medium term, negative equity can impair borrowing capacity, elevate creditor scrutiny, and likely force dilutive financing if clinical programs require additional capital before revenue generation.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA End-of-Phase 2 Support
FDA written End-of-Phase 2 support materially de-risks the regulatory path by confirming Phase 2 data can justify a pivotal trial. This validation supports a clear development plan toward a registrational Phase 3, increases credibility with partners and funders, and solidifies a multi-quarter development roadmap.
Read all positive factors
Armata Pharmaceuticals (ARMP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$428.24M
Dividend YieldN/A
Average Volume (3M)536.86K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth-7.55%
EPS Growth-13.09%
CountryUS
Employees60
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.42
Shares Outstanding36,632,774
10 Day Avg. Volume121,090
30 Day Avg. Volume536,864
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.04
Price to Sales (P/S)46.41
P/FCF Ratio-8.65
Enterprise Value/Market Cap1.75
Enterprise Value/Revenue153.17
Enterprise Value/Gross Profit222.70
Enterprise Value/Ebitda-25.30
Forecast
1Y Price Target
$17.50Price Target Upside35.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.09
Revenue Forecast (FY)N/A
Armata Pharmaceuticals Business Overview & Revenue Model
Company Description
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-bas...
How the Company Makes Money
Armata Pharmaceuticals has historically generated little to no recurring revenue because it is primarily a clinical-stage drug developer and does not sell approved commercial products. To the extent the company generates revenue, it may come from ...
Armata Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.90M | 5.17M | 4.53M | 5.51M | 4.47M |
| Gross Profit | 3.37M | -29.25M | 3.56M | -29.51M | -15.54M |
| EBITDA | -29.69M | -41.11M | -65.45M | -36.05M | -21.92M |
| Net Income | -173.80M | -18.92M | -69.05M | -36.92M | -23.16M |
Balance Sheet | |||||
| Total Assets | 76.88M | 86.44M | 98.36M | 107.88M | 69.77M |
| Cash, Cash Equivalents and Short-Term Investments | 8.69M | 9.29M | 13.52M | 14.85M | 10.29M |
| Total Debt | 288.02M | 126.52M | 120.37M | 48.81M | 37.99M |
| Total Liabilities | 295.48M | 134.46M | 130.43M | 71.80M | 44.37M |
| Stockholders Equity | -218.60M | -48.02M | -32.06M | 36.08M | 25.40M |
Cash Flow | |||||
| Free Cash Flow | -26.30M | -39.43M | -55.57M | -34.69M | -24.88M |
| Operating Cash Flow | -25.76M | -37.55M | -47.42M | -32.48M | -23.57M |
| Investing Cash Flow | -542.00K | -1.88M | -8.13M | -2.21M | -1.30M |
| Financing Cash Flow | 25.61M | 34.96M | 53.99M | 44.02M | 25.52M |
Armata Pharmaceuticals Technical Analysis
Positive
12.88
Price Trends
9.63
Positive
7.99
Positive
5.63
Positive
Market Momentum
0.57
Negative
60.75
Neutral
73.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARMP, the sentiment is Positive. The current price of 12.88 is above the 20-day moving average (MA) of 9.78, above the 50-day MA of 9.63, and above the 200-day MA of 5.63, indicating a bullish trend. The MACD of 0.57 indicates Negative momentum. The RSI at 60.75 is Neutral, neither overbought nor oversold. The STOCH value of 73.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARMP.
Armata Pharmaceuticals Risk Analysis
Armata Pharmaceuticals disclosed 27 risk factors in its most recent earnings report. Armata Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Armata Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $153.29M | 1.57 | 43.14% | ― | ― | 814.20% | |
55 Neutral | $428.24M | -1.31 | 158.91% | ― | -7.55% | -13.09% | |
53 Neutral | $181.96M | -4.05 | -86.91% | ― | -87.59% | 11.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $47.06M | 0.54 | -225.83% | ― | -14.92% | 72.81% | |
49 Neutral | $57.41M | -3.81 | ― | ― | ― | 21.48% | |
46 Neutral | $38.20M | -2.04 | -83.24% | ― | -100.00% | 55.10% |
* Healthcare Sector Average
ARMP
Armata Pharmaceuticals
12.88
11.73
1020.00%
VERU
Veru
2.42
-2.84
-53.99%
ORMP
Oramed Pharm
3.80
1.72
82.87%
ELUT
Elutia
1.14
-1.00
-46.73%
ADAG
Adagene
3.81
2.21
138.13%
INKT
MiNK Therapeutics
13.51
5.76
74.32%
Armata Pharmaceuticals Corporate Events
Shareholder Meetings
Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting
Neutral
Apr 2, 2026
Armata Pharmaceuticals has scheduled its 2026 annual meeting of stockholders for June 11, 2026, at 8:30 a.m. Pacific Time at its principal executive offices in Los Angeles, California, with the meeting date and venue potentially subject to change ...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay
Positive
Mar 19, 2026
On March 19, 2026, Armata Pharmaceuticals said it will delay releasing its fourth-quarter and full-year 2025 financial results while it completes its reporting, but still expects to file its annual report by the March 31 deadline. At the same time...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy
Positive
Feb 23, 2026
On February 23, 2026, Armata Pharmaceuticals announced that the U.S. Food and Drug Administration granted Qualified Infectious Disease Product designation to AP-SA02, its intravenous multi-phage candidate for adjunct treatment of complicated Staph...
Business Operations and StrategyPrivate Placements and Financing
Armata Extends Innoviva Credit, Warrants and Voting Pact
Positive
Jan 26, 2026
On January 23, 2026, Armata Pharmaceuticals amended four existing credit agreements with Innoviva Strategic Opportunities LLC, extending the maturity date on each facility to June 1, 2027, thereby lengthening its debt profile and reinforcing acces...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Armata Wins FDA Support to Advance Bacteriophage to Phase 3
Positive
Jan 13, 2026
On January 13, 2026, Armata Pharmaceuticals announced it had received an End-of-Phase 2 written response from the U.S. Food and Drug Administration supporting advancement of its intravenously administered Staphylococcus aureus bacteriophage candid...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.